When to Order Imaging for Staging and Follow-up of Melanoma: ACR Appropriateness Decoded

When to Order Imaging for Staging and Follow-up of Melanoma: ACR Appropriateness Decoded

A new diagnosis of melanoma lands on your desk. The pathology report is clear, but the next step—staging—is less so. Does this patient need a full-body PET/CT, or is clinical follow-up sufficient? Ordering unnecessary advanced imaging can lead to incidental findings, patient anxiety, and increased costs, while under-imaging risks missing critical metastatic disease that could alter management. For clinicians making these decisions, especially after hours or with complex cases, the path forward can be ambiguous. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria for staging and follow-up of melanoma, providing a clear, evidence-based framework for choosing the right imaging study for the right patient at the right time.

What Does ACR Staging and Follow-up of Melanoma Cover?

This ACR topic, developed by the Systemic Oncology panel, provides imaging recommendations for adult patients with cutaneous, muco-cutaneous, and ocular melanoma. The criteria are organized by distinct clinical scenarios, covering initial staging, post-treatment surveillance, and evaluation of suspected recurrence. Specifically, these guidelines address which imaging modalities are most appropriate based on the patient’s initial diagnosis, pathologic findings (such as positive sentinel lymph nodes), and clinical signs or symptoms of regional or distant disease.

These recommendations focus on the role of imaging in determining the extent of disease and monitoring for recurrence. They do not cover the initial diagnosis of a primary skin lesion, which is typically done via clinical examination and biopsy. The criteria are intended to guide imaging decisions after a pathologic diagnosis of melanoma has been established. They help differentiate between low-risk patients who generally do not require baseline systemic imaging and high-risk patients for whom modalities like FDG-PET/CT or MRI are essential for proper management.

What Imaging Should I Order for Staging and Follow-up of Melanoma? Recommendations by Clinical Scenario

The appropriate imaging for melanoma depends entirely on the clinical context, including the initial pathology and the presence or absence of symptoms. The ACR provides clear guidance for several common scenarios.

For an adult with a newly diagnosed cutaneous or muco-cutaneous melanoma with no signs or symptoms of regional or metastatic disease, and no pathologic evidence of regional nodal metastases, most cross-sectional imaging is deemed Usually Not Appropriate. This includes CT, MRI, and FDG-PET/CT. The low pretest probability of finding distant metastases in this population does not justify the radiation exposure or cost of these studies. The one exception is Lymphoscintigraphy of the area of interest, which is rated Usually Appropriate for identifying the sentinel lymph node basin prior to biopsy.

The recommendation changes significantly for an adult with a newly diagnosed melanoma who has higher-risk features. This includes patients with a microscopic satellite in the primary lesion, positive lymph nodes on sentinel biopsy, or suspected regional lymph node involvement. In this scenario, FDG-PET/CT whole body is rated Usually Appropriate for detecting regional and distant metastatic disease. Other modalities like contrast-enhanced CT of the chest or abdomen/pelvis and MRI of the head or abdomen/pelvis are considered May be Appropriate depending on the specific clinical question.

For routine surveillance in an adult who had negative regional lymph nodes and no metastatic disease at diagnosis, the role of imaging is less certain. FDG-PET/CT whole body, CT chest with or without IV contrast, and MRI head without and with IV contrast are all rated May be Appropriate. The decision to perform surveillance imaging in this group should be based on the primary tumor characteristics and an individualized assessment of recurrence risk. For guidance on specific protocols, see our article on CT Brain Without Contrast.

In contrast, for surveillance in an adult with known positive regional lymph nodes or metastatic disease at initial diagnosis, imaging is more strongly indicated. FDG-PET/CT whole body, CT chest with IV contrast, and MRI head without and with IV contrast are all rated Usually Appropriate. These studies are critical for monitoring treatment response and detecting early recurrence in this high-risk population.

When there is clinical suspicion for recurrent cutaneous, muco-cutaneous, or ocular melanoma, a comprehensive imaging evaluation is warranted. FDG-PET/CT whole body is Usually Appropriate and often the preferred single modality. Targeted studies, including US of the area of interest, MRI head without and with IV contrast, MRI abdomen and pelvis without and with IV contrast, and contrast-enhanced CT of the chest and abdomen/pelvis are also Usually Appropriate to evaluate specific sites of suspected disease.

Finally, for the initial staging of ocular melanoma, imaging is directed at the most common sites of metastasis. MRI abdomen and pelvis without and with IV contrast, MRI head without and with IV contrast, and FDG-PET/CT whole body are all considered Usually Appropriate. The liver is a frequent site of metastasis from ocular melanoma, making dedicated abdominal imaging crucial. While contrast-enhanced CT of the abdomen is rated May be Appropriate, non-contrast studies are generally not sufficient. For a review of non-contrast abdominal CT protocols in other contexts, see our guide on CT Abdomen/Pelvis Without Contrast (Renal Stone).

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Follow-up of Melanoma Imaging: Radiation Dose Tradeoffs

While melanoma is less common in children than adults, imaging decisions in pediatric patients require careful consideration of long-term risks from ionizing radiation. The ACR provides distinct pediatric relative radiation level (RRL) estimates, reflecting the principle of As Low As Reasonably Achievable (ALARA). For many CT and nuclear medicine studies, the pediatric RRL is in a lower tier than the adult equivalent, indicating that protocols should be optimized to deliver a smaller radiation dose.

For example, an FDG-PET/CT of the whole body carries an RRL of ☢ ☢ ☢ ☢ (10-30 mSv) for adults but ☢ ☢ ☢ ☢ (3-10 mSv) for pediatric patients. This highlights the importance of using pediatric-specific protocols that adjust technical parameters like tube current (for CT) and radiotracer dose (for PET) based on patient size and weight. When non-ionizing alternatives like MRI or ultrasound can provide the necessary diagnostic information, they are often preferred in younger patients to minimize cumulative radiation exposure over their lifetime. The choice of imaging must always balance the diagnostic benefit against the potential long-term risks.

Imaging Protocol Details for Staging and Follow-up of Melanoma

Once you’ve decided on the right study based on the ACR criteria, ensuring it is performed correctly is the next critical step. The specific imaging protocol—including contrast timing, slice thickness, and reconstruction algorithms—can significantly impact diagnostic quality. Our library of protocol guides provides detailed, practical information for executing many of the studies recommended in these guidelines.

• CT Brain Without Contrast
• CT Abdomen/Pelvis Without Contrast (Renal Stone)

Tools to Help You Order the Right Study

Navigating imaging guidelines can be complex. GigHz offers several tools designed to support clinical decision-making and streamline the ordering process.

For scenarios not covered in this article, the ACR Appropriateness Criteria Lookup provides a comprehensive, searchable interface for all ACR topics. It helps you quickly find evidence-based recommendations for hundreds of clinical variants.

To ensure studies are performed to the highest standard, the Imaging Protocol Library offers detailed, step-by-step guides for a wide range of CT, MRI, and other imaging procedures. These resources are designed for both ordering clinicians and imaging technologists.

When discussing the risks and benefits of imaging with patients, especially concerning radiation, the Radiation Dose Calculator is an invaluable tool. It helps estimate effective dose for various studies and can be used to track cumulative exposure for patients requiring serial imaging.

Why is imaging generally not recommended for early-stage, asymptomatic melanoma?

For patients with thin melanomas (e.g., stage I) and no clinical signs of spread, the probability of detecting distant metastatic disease on imaging is very low. The potential harms—including radiation exposure, cost, patient anxiety, and workup of incidental findings—outweigh the potential benefits. Clinical examination and follow-up are the standard of care for this group.

What is the primary role of FDG-PET/CT in melanoma staging and surveillance?

FDG-PET/CT is a highly sensitive whole-body imaging modality for detecting metastatic melanoma, which is typically FDG-avid. Its primary role is in the initial staging of high-risk patients (e.g., those with positive sentinel nodes) and in the evaluation of suspected recurrence. It is also a key tool for monitoring response to systemic therapies in patients with advanced disease.

How often should surveillance imaging be performed for melanoma?

The optimal frequency and duration of surveillance imaging are not definitively established and depend on the initial stage, tumor characteristics, and treatment history. The ACR criteria specify *which* studies are appropriate for surveillance but do not dictate a specific schedule. Guidelines from organizations like the National Comprehensive Cancer Network (NCCN) often suggest imaging schedules based on risk stratification, which should be tailored to the individual patient.

When is brain MRI indicated for melanoma surveillance?

Brain MRI is the most sensitive modality for detecting brain metastases. It is rated as ‘Usually Appropriate’ for surveillance in patients with known positive regional nodes or prior metastatic disease (Stage III/IV), as this group has a higher risk of central nervous system involvement. For patients with lower-stage disease, routine brain MRI surveillance is typically not recommended unless the patient develops neurologic symptoms.

Is there a role for whole-body MRI instead of PET/CT?

Whole-body MRI (WB-MRI) is an emerging technique for cancer staging that avoids ionizing radiation. While it is not explicitly listed as a primary option in these specific ACR variants for melanoma, it is used at some centers, particularly for pediatric patients, pregnant women, or patients requiring frequent imaging where cumulative radiation dose is a concern. Its sensitivity and specificity compared to PET/CT for melanoma are still areas of active research.

Why is lymphoscintigraphy only appropriate for initial staging of clinically node-negative patients?

Lymphoscintigraphy is a nuclear medicine technique used to map the lymphatic drainage pathways from a primary tumor site to the regional lymph node basin. Its purpose is to identify the “sentinel” lymph node(s)—the first node(s) to receive drainage. This allows the surgeon to perform a targeted sentinel lymph node biopsy (SLNB). If a patient already has clinically obvious nodal disease (palpable nodes) or pathologically confirmed nodal metastases, the drainage pattern is less relevant, and the patient proceeds to further staging and treatment for node-positive disease.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026